Intersect Capital LLC Has $374,000 Holdings in Bristol-Myers Squibb Co (BMY)

Intersect Capital LLC lifted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.0% in the first quarter, Holdings Channel reports. The fund owned 7,846 shares of the biopharmaceutical company’s stock after acquiring an additional 446 shares during the quarter. Intersect Capital LLC’s holdings in Bristol-Myers Squibb were worth $374,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc boosted its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after purchasing an additional 1,229,553 shares during the period. BKD Wealth Advisors LLC boosted its position in Bristol-Myers Squibb by 3.8% during the 4th quarter. BKD Wealth Advisors LLC now owns 22,148 shares of the biopharmaceutical company’s stock valued at $1,151,000 after purchasing an additional 815 shares during the period. Joel Isaacson & Co. LLC boosted its position in Bristol-Myers Squibb by 18.9% during the 4th quarter. Joel Isaacson & Co. LLC now owns 15,321 shares of the biopharmaceutical company’s stock valued at $735,000 after purchasing an additional 2,435 shares during the period. Gradient Investments LLC boosted its position in Bristol-Myers Squibb by 1,945.9% during the 4th quarter. Gradient Investments LLC now owns 180,549 shares of the biopharmaceutical company’s stock valued at $9,385,000 after purchasing an additional 171,724 shares during the period. Finally, Nachman Norwood & Parrott Inc acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $2,546,000. 76.62% of the stock is owned by institutional investors.

Shares of BMY stock opened at $47.74 on Thursday. The company has a quick ratio of 1.79, a current ratio of 1.93 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69. The firm has a market cap of $77.58 billion, a price-to-earnings ratio of 11.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.77.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the previous year, the firm posted $0.94 EPS. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were issued a $0.41 dividend. The ex-dividend date was Thursday, April 4th. This represents a $1.64 annualized dividend and a dividend yield of 3.44%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

BMY has been the subject of a number of analyst reports. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, March 5th. BMO Capital Markets restated a “buy” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Credit Suisse Group reiterated a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Bank of America set a $53.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, January 25th. Finally, Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target for the company. in a research report on Monday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $56.88.

In other news, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the sale, the insider now owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Theodore R. Samuels II acquired 5,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was purchased at an average price of $47.29 per share, with a total value of $236,450.00. Following the acquisition, the director now owns 27,000 shares of the company’s stock, valued at $1,276,830. The disclosure for this purchase can be found here. Corporate insiders own 0.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intersect Capital LLC Has $374,000 Holdings in Bristol-Myers Squibb Co (BMY)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/23/intersect-capital-llc-has-374000-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What is the Bid-Ask Spread?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.